scispace - formally typeset
Open AccessJournal ArticleDOI

Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins

TLDR
In this article, the authors exploited the potential of the asialoglycoprotein receptor (ASGPR), a lysosomal targeting receptor specifically expressed on liver cells, for the degradation of extracellular proteins including membrane proteins.
Abstract
Targeted protein degradation (TPD) technology has drawn significant attention from researchers in both academia and industry. It is rapidly evolved as a new therapeutic modality and also a useful chemical tool in selectively depleting various protein targets. As most efforts focus on cytosolic proteins using PROteolysis TArgeting Chimera (PROTAC), LYsosome TArgeting Chimera (LYTAC) recently emerged as a promising technology to deliver extracellular protein targets to lysosome for degradation through the cation-independent mannose-6-phosphate receptor (CI-M6PR). In this study, we exploited the potential of the asialoglycoprotein receptor (ASGPR), a lysosomal targeting receptor specifically expressed on liver cells, for the degradation of extracellular proteins including membrane proteins. The ligand of ASGPR, triantennary N-acetylgalactosamine (tri-GalNAc), was conjugated to biotin, antibodies, or fragments of antibodies to generate a new class of degraders. We demonstrated that the extracellular protein targets could be successfully internalized and delivered into lysosome for degradation in liver cell lines specifically by these degraders. This work will add a new dimension to TPD with cell type specificity.

read more

Citations
More filters
Journal ArticleDOI

Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs.

TL;DR: Targeted protein degradation (TPD) as discussed by the authors is a novel and innovative chemical tool and therapeutic modality that facilitates complete removal of the protein molecules from within or outside the cell.
Journal ArticleDOI

Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation.

TL;DR: A covalent nanobody-based PROTAC strategy, termed GlueTAC, for targeted membrane protein degradation with high specificity and efficiency, and sustained eradication of tumor surface antigens both in vitro and in vivo.
Journal ArticleDOI

Bifunctional small molecules that mediate the degradation of extracellular proteins.

TL;DR: In this article, the authors developed a class of modular, bifunctional synthetic molecules called MoDE-As (molecular degraders of extracellular proteins through the asialoglycoprotein receptor (ASGPR)), which mediate the degradation of extacellular proteins.
Journal ArticleDOI

Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.

TL;DR: The latest progress in improving the in vivo degradation efficacy of PROTACs through delivery strategies is surveyed, design principles for PROTAC-based delivery systems are outlined, and the future opportunities in this field are outlooked.
Journal ArticleDOI

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.

Abstract: Classic small molecule inhibitors that directly target pathogenic proteins typically rely on the accessible binding sites to achieve prolonged occupancy and influence protein functions. The emerging targeted protein degradation (TPD) strategies exemplified by PROteolysis TArgeting Chimeras (PROTACs) are revolutionizing conventional drug discovery modality to target proteins of interest (POIs) that were categorized as "undruggable" before, however, these strategies are limited within intracellular POIs. The novel new degrader technologies such as LYsosome-TArgeting Chimaeras (LYTACs) and Antibody-based PROTACs (AbTACs) have been successfully developed to expand the scope of TPD to extracellular and membrane proteins, fulfilling huge unmet medical needs. Here, we systematically review the currently viable protein degradation strategies, emphasize that LYTACs and AbTACs turn a new avenue for the development of TPD, and highlight the potential challenges and directions in this vibrant field.
References
More filters
Journal ArticleDOI

Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules

TL;DR: Peptide aldehydes that inhibit major peptidase activities of the 20S and 26S proteasomes are shown to reduce the degradation of protein and ubiquitinated protein substrates by 26S particles.
Journal ArticleDOI

Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation.

TL;DR: It is shown that MetAP-2 can be tethered to SCFβ-TRCP, ubiquitinated, and degraded in a Protac-1-dependent manner, which may be useful for conditional inactivation of proteins, and for targeting disease-causing proteins for destruction.
Journal ArticleDOI

Calculation of hydrodynamic properties of globular proteins from their atomic-level structure.

TL;DR: The solution properties, including hydrodynamic quantities and the radius of gyration, of globular proteins are calculated from their detailed, atomic-level structure, using bead-modeling methodologies described in the previous article, using a HYDROPRO public-domain computer program.
Journal ArticleDOI

Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin. Dependence on fine structural features.

TL;DR: It was found that the number of Gal residues/cluster and their branching mode are major determinants of binding affinity of ligands to the hepatic lectin on the surface of hepatocytes.
Journal ArticleDOI

Targeted protein degradation: expanding the toolbox.

TL;DR: Opportunities and challenges for expanding the applicability of targeted protein degradation are discussed, with a focus on the large family of E3 ubiquitin ligases that have a key role in the process.
Related Papers (5)